“What they would target with a typical pandemic, like influenza, is making 50 million doses at a plant within six months facilities that mass produce cGMP mRNA vaccines.
To design, build and validate a new plant…you’re talking two years. And we don’t have that kind of time. But to convert? Assuming it’s a perfect scenario…you probably need six months.”